Showing 2011-2020 of 4063 results for "".
- B+L: Investigational In Vitro Data Indicates Complete Inactivation Of SARS-CoV-2 With Lumify and Besivance Eye Dropshttps://modernod.com/news/bausch-health-announces-investigational-in-vitro-data-indicating-complete-inactivation-of-sars-cov-2-with-lumify-and-besivance-eye-drops/2478558/Bausch Health Companies and Bausch + Lomb announced the results of new investigational in vitro data showing that two benzalkonium chloride (BAK) preserved eye drops, Lumify (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops and Besivance (besifloxacin ophthalmic
- GSK, Vir Biotechnology Move Anti-SARS-CoV-2 Monoclonal Antibody Into Phase 3https://modernod.com/news/gsk-vir-biotechnology-move-anti-sars-cov-2-monoclonal-antibody-into-phase-3/2478385/GlaxoSmithKline and partner Vir Biotechnology announced that the COMET-ICE study evaluating VIR-7831 as an early treatment for COVID-19 patients deemed to be at high risk of hospitalization will proceed into phase 3 testing, with preliminary results coming possibly before the end of this year. Th
- US to PayNearly $2 Billion for 100 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/us-to-paynearly-2-billion-for-100-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478067/Pfizer and BioNTech announced that the US government agreed to pay $1.95 billion for an initial order of 100 million doses of BNT162, an mRNA-based COVID-19 vaccine candidate being jointly developed by the companies. Under the deal, the government can also acquire up to 500 million more doses.
- AstraZeneca Targeting Over 2 Billion COVID-19 Vaccine Doses After Latest Dealshttps://modernod.com/news/astrazeneca-targeting-over-2-billion-covid-19-vaccine-doses-after-latest-deals/2477865/AstraZeneca said it signed agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance and the Serum Institute of India (SII) in a move aimed at broadening global access to an experimental COVID-19 vaccine being developed at the University of Oxford. The
- Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for DR and DME from Apexian Pharmaceuticalshttps://modernod.com/news/ocuphire-pharma-announces-in-license-of-phase-2-oral-small-molecule-drug-candidate-for-dr-and-dme-from-apexian-pharmaceuticals/2477254/Ocuphire Pharma announced that it has entered into an agreement with Apexian Pharmaceuticals, granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first
- Ocuphire Pharma Raises Over $5 Million to Complete Late Phase 2 Clinical Trials for Ophthalmic Disordershttps://modernod.com/news/ocuphire-pharma-raises-over-5-million-to-complete-late-phase-2-clinical-trials-for-ophthalmic-disorders/2476760/Ocuphire Pharma announced that it has closed on over $5 million of financing. Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol. Nyxol is a novel eye drop treatment for multiple front-of-the-eye disorders, including night vision distur
- TopiVert Announces Publication of Data from its Positive Phase 2 Study of TOP1630 in Dry Eye Diseasehttps://modernod.com/news/topivert-announces-publication-of-data-from-its-positive-phase-2-study-of-top1630-in-dry-eye-disease/2476303/TopiVert Pharma, a clinical-stage biotechnology company developing non-systemic kinase inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular diseases, announces the publication of the
- Nicox Announces FDA Acceptance of Investigational NDA for NCX 4251 Phase 2 Trial in Blepharitishttps://modernod.com/news/nicox-announces-fda-acceptance-of-investigational-nda-for-ncx-4251-phase-2-trial-in-blepharitis/2479597/Nicox SA announced that the FDA has completed its review of the company’s investigational new drug (IND) application for NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the fi
- Oculis In-Licenses Phase 2 Topical Anti-TNF Alpha Antibody From Novartishttps://modernod.com/news/oculis-in-licenses-phase-2-topical-anti-tnf-alpha-antibody-from-novartis/2476220/Oculis has entered into an agreement to in-license a novel topical anti-TNF alpha antibody from Novartis. Terms of the deal were not disclosed. The compound, named LME 636, is based on a proprietary single-chain antibody fragment technology specifically de
- GenSight Biologics Enrolls First Subject in PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Drug Candidatehttps://modernod.com/news/gensight-biologics-enrolls-first-subject-in-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-drug-candidate/2479731/GenSight Biologics announced that the first subject was treated in the first-in-man PIONEER phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. “We are thrilled to see our second lead program, GS030, now entering the clinic. This is a fantastic achi